It has also been implicated in tumorigenesis, cancer progression and targeted therapy resistance in several types of cancer [56] Among the major therapeutic representatives targeting HER3, we can find mAbs such as lumretuzumab, patritumab and zenocutuzumab and small molecules like lapatinib, erlotinib, gefitinib, afatinib and neratinib [57,58,59,60]. Here, ERBB3 is linked to cancer.